News
Stanford Study Identifies Why Ozempic and Wegovy Don't Work in About 1 in 10 Patients
A Stanford Medicine study identifies a genetic variant in about 10% of people that may reduce response to GLP-1 drugs like Ozempic and Wegovy, offering new insight into why these widely used diabetes and weight-loss treatments fail for some patients and highlighting the future of precision medicine in Type 2 diabetes care.
→
Intermittent Fasting Is Rewiring Your Brain and Gut at the Same Time — New Research Explains Why It's Finally Working for Americans Who Failed Every Other Diet
A new study found that intermittent fasting doesn't just change your waistline — it changes your gut bacteria and the structure of your brain's cravings circuitry simultaneously.
→
Los Angeles Seniors Hit the $2,000 Medicare Drug Cap for the First Time — Here's What Happens to Their Prescriptions for the Rest of 2026
Los Angeles seniors are reaching Medicare's new $2,000 annual drug cost cap for the first time in 2026, triggering full drug coverage for the rest of the year and marking a major shift in prescription affordability under recent federal reforms.
→
